Modality
Nanobody
MOA
WRNi
Target
PRMT5
Pathway
RAS/MAPK
CKDHSFSGS
Development Pipeline
Preclinical
~Jun 2015
→ ~Sep 2016
Phase 1
~Dec 2016
→ ~Mar 2018
Phase 2
~Jun 2018
→ ~Sep 2019
Phase 3
~Dec 2019
→ ~Mar 2021
NDA/BLA
Jun 2021
→ Dec 2027
NDA/BLACurrent
NCT08320096
2,864 pts·HS
2021-06→2027-12·Active
2,864 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (1)
2027-12-221.7y awayPh3 Readout· HS
Trial Timeline
Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q4
NDA/BLA
Active
Catalysts
Ph3 Readout
2027-12-22 · 1.7y away
HS
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08320096 | NDA/BLA | HS | Active | 2864 | LiverFat |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Nirarelsin | Johnson & Johnson | Phase 2 | PRMT5 | |
| MRK-853 | Merck & Co | Phase 1 | PRMT5 | |
| ABB-1817 | AbbVie | Phase 3 | SHP2 | |
| BMY-7975 | Bristol-Myers Squibb | Phase 1 | MALT1 | |
| Geliderotide | Sanofi | Phase 1/2 | PRMT5 | |
| Capifutibatinib | Sanofi | Approved | PRMT5 | |
| NVO-9615 | Novo Nordisk | Phase 2/3 | PRMT5 | |
| GSK-4334 | GSK | Preclinical | CD47 | |
| Suracagene | GSK | Phase 3 | PRMT5 | |
| AMG-2752 | Amgen | Preclinical | MDM2 |